Get the Stockscreener App
12.86
10.43%
1.215
After Hours:
12.70
-0.16
-1.24%
Agomab Therapeutics Nv Adr stock is traded at $12.86, with a volume of 138.05K.
It is up +10.43% in the last 24 hours and down -20.17% over the past month.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
See More
Previous Close:
$11.64
Open:
$11.93
24h Volume:
138.05K
Relative Volume:
1.88
Market Cap:
$632.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.15%
1M Performance:
-20.17%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.76
$13.49
1-Week Range:
$10.50
$14.63
52-Week Range:
$10.50
$17.45
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Name
Agomab Therapeutics Nv Adr
Sector
Industry
Phone
-
Address
-
Compare AGMB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
12.86 | 573.16M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | JP Morgan | Overweight |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Morgan Stanley | Overweight |
Agomab Therapeutics Nv Adr Stock (AGMB) Latest News
Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView
EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView
Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView
EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView
Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView
Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Agomab closes $200 million IPO on NASDAQ - Investing.com India
Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
Agomab Announces Closing of Initial Public Offering - Benzinga
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Mint
Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada
Agomab prices IPO at $16 per share, aims to raise $200 million - Investing.com Australia
Agomab prices IPO at $16 per share, aims to raise $200 million By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Agomab Therapeutics Nv Adr Stock (AGMB) Financials Data
There is no financial data for Agomab Therapeutics Nv Adr (AGMB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):